Stanford researchers in the Cochran Lab have patented a potential pancreatic cancer therapeutic approach using novel agents that bind tightly to and inhibit a cancer factor called LIF (leukemia inhibitory factor).
SARS-CoV2 is known to gain entry into epithelial cells through the association of its viral spike protein with the ACE2 receptor, which is widely expressed on epithelial cell types.
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, making it the leading cause of cancer-related deaths globally. Post-surgical recurrence and treatment resistance are the main causes of cancer-related mortality.
Osteopontin is a protein involved in the pathogenesis of cancer and chronic inflammatory diseases. Antibodies are a powerful tool that can be used to target this protein and regulate its pathway.
Researchers at Stanford have developed a novel strategy to enhance vaccine efficacy using mRNA lipid nanoparticles (LNPs) encoding immunostimulatory cytokines.
Stanford researchers in Dr. Taia Wang's lab have developed a technology that utilizes swainsonine to enhance the cytotoxic potency of monoclonal antibodies, thereby improving their efficacy in cancer and autoimmune disease treatments.
Researchers at Stanford University have discovered that donor-specific anti-HLA antibodies can be used to detect and treat graft-versus-host disease (GVHD) in transplant recipients after allogenic transplantation.
Scientists in Dr. Howard Chang's lab have developed ESCAPE-seq (Enhanced Single Chain Antigen Presentation sequencing) to identify novel neoantigen sequences for the development of immunotherapies.
Stanford scientists in Dr. Michael Lin's lab have established the use of B-cell reducing agents to improve an oncolytic virus (OV) therapy to rewire cancer signaling while limiting the production of antibodies against the virus in mouse studies.
Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.
Aging-associated mitochondrial dysfunction (mito-dysfunction) affects every cell system in our body. Mito-dysfunction includes reduced quality of mitochondrial DNA (mtDNA), irregular generation of reactive oxygen species, and membrane potential.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.